Jazz Pharmaceuticals PLC (JAZZ)

NASDAQ


	Symbol		Exchange		Currency
	JAZZ		NASDAQ		USD	Real-time
	J7Z		Frankfurt		EUR	Delayed

Currency in USD

Disclaimer

107.32

-0.30(-0.28%)

Closed09/10

After Hours

106.74-0.58(-0.54%)

09/10

Fair Value

Day's Range

106.76

109.26

52 wk Range

99.06

137.38

Jazz Pharma (JAZZ) Income Statement & Profits

Assess the Jazz Pharma Income Statement (earnings report), showing the company's financial performance from operating and non operating activities such as revenue, expenses and income. Check assets and liabilities, diluted earnings per share (EPS), and net income after taxes for the last 4 periods (either quarterly or annually).

Investors who need greater depth or who want to customise how data is presented to fit their own investment styles are able to do so via their very own InvestingPro account.

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

2,161.76

2,363.57

3,094.24

3,659.37

3,834.2

Total Revenues Growth

+14.32%

+9.34%

+30.91%

+18.26%

+4.78%

Cost Of Revenues

127.93

148.92

217.68

267.13

284.13

Gross Profit

2,033.83

2,214.65

2,876.56

3,392.25

3,550.07

Gross Profit Growth

+14.95%

+8.89%

+29.89%

+17.93%

+4.65%

Gross Profit Margin %

94.08%

93.7%

92.97%

92.7%

92.59%

Other Operating Expenses, Total

1,391.48

1,449.19

2,401.3

2,553.11

2,739.35

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+32.09%	+4.15%	+65.7%	+6.32%	+7.29%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	274.8	309.76	476.33	555.41	823.89
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	761.87	879.85	1,399.2	1,398.53	1,307.17
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

642.35

765.46

475.26

839.14

810.73

Operating Income Growth

-10.28%

+19.17%

-37.91%

+76.56%

-3.39%

EBIT Margin %

29.71%

32.39%

15.36%

22.93%

21.14%

Net Interest Expenses

-72.26

-99.71

-278.77

-288.24

-289.44

Net Interest Expenses Growth

+6.25%

-37.98%

-179.59%

-3.4%

-0.41%

Interest Expense, Total

-72.26

-110.81

-280.57

-299.74

-354.54

Interest And Investment Income

-

11.1

1.8

11.5

65.1

Other Non Operating Expenses, Total

-9.9

-6.23

-5.06

-28.94

5.78

EBT, Excl. Unusual Items

560.19

659.52

191.43

521.97

527.07

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-109.98

-387.39

-

-577.8

-80.7

EBT, Incl. Unusual Items

450.21

272.13

-113.55

-382.71

294.92

EBT, Incl. Unusual Items Growth

-14.61%

-39.55%

-141.73%

-237.03%

+177.06%

EBT, Incl. Unusual Items Margin

20.83%

11.51%

-3.67%

-10.46%

7.69%

Income Tax Expense

-73.15

33.52

216.12

-158.65

-119.91

Net Income to Company

523.37

238.62

-329.67

-224.06

414.83

Minority Interest

-

-

-

-

-

Net Income

523.37

238.62

-329.67

-224.06

414.83

Net Income Growth

+17.06%

-54.41%

-238.16%

+32.03%

+285.14%

Net Income Margin %

24.21%

10.1%

-10.65%

-6.12%

10.82%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

523.37

238.62

-329.67

-224.06

414.83

Basic EPS - Continuing Operations

9.22

4.28

-5.52

-3.58

6.55

Basic EPS - Continuing Operations Growth

+23.72%

-53.56%

-228.94%

+35.13%

+282.94%

Diluted EPS - Continuing Operations

9.09

4.22

-5.52

-3.58

6.1

Diluted EPS - Continuing Operations Growth

+24.52%

-53.58%

-230.87%

+35.13%

+270.3%

Basic Weighted Average Shares Outstanding

56.75

55.71

59.69

62.54

63.29

Diluted Weighted Average Shares Outstanding

57.55

56.52

59.69

62.54

72.07

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

1,012.51

1,043.72

1,027.75

1,468.62

1,449.42

EBITDA Growth

+8.56%

+3.08%

-1.53%

+42.9%

-1.31%

EBITDA Margin %